Paysign/$PAYS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Paysign
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
Ticker
$PAYS
Sector
Primary listing
Employees
173
Headquarters
Website
Paysign Metrics
BasicAdvanced
$301M
46.01
$0.12
0.78
-
Price and volume
Market cap
$301M
Beta
0.78
52-week high
$8.88
52-week low
$1.80
Average daily volume
619K
Financial strength
Current ratio
1.107
Quick ratio
0.378
Long term debt to equity
5.286
Total debt to equity
6.448
Profitability
EBITDA (TTM)
11.952
Gross margin (TTM)
59.99%
Net profit margin (TTM)
9.90%
Operating margin (TTM)
7.41%
Effective tax rate (TTM)
15.42%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
1.69%
Return on equity (TTM)
19.65%
Valuation
Price to earnings (TTM)
46.009
Price to revenue (TTM)
4.325
Price to book
7.12
Price to tangible book (TTM)
21.4
Price to free cash flow (TTM)
-17.09
Free cash flow yield (TTM)
-5.85%
Free cash flow per share (TTM)
-0.323
Growth
Revenue change (TTM)
27.84%
Earnings per share change (TTM)
-17.83%
3-year revenue growth (CAGR)
27.14%
10-year revenue growth (CAGR)
20.56%
3-year earnings per share growth (CAGR)
106.55%
10-year earnings per share growth (CAGR)
6.45%
What the Analysts think about Paysign
Analyst ratings (Buy, Hold, Sell) for Paysign stock.
Bulls say / Bears say
Paysign's Q2 2025 revenue grew 33.1% year-over-year to $19.08 million, exceeding analyst expectations, with adjusted EBITDA up 101.8% to $4.51 million and gross margin improving to 61.6% (Reuters via TradingView).
Pharma patient affordability revenue jumped 189.9% in Q2 2025, fueled by new program launches and greater claims processing volume, highlighting strong demand for Paysign's solutions (Reuters via TradingView).
Paysign increased its full-year 2025 revenue outlook to $76.5 million–$78.5 million and expects Q3 2025 revenue between $19.5 million–$20.5 million, signaling management’s confidence in sustained growth (Reuters via TradingView).
Plasma segment revenue declined 4.7% in Q2 2025 due to industry-wide oversupply despite the addition of 123 net plasma centers, putting pressure on Paysign's historically highest-margin business (Reuters via TradingView).
Paysign reported negative $2.39 million in operating cash flow year-to-date through Q2 2025, indicating issues with cash conversion and working capital management despite net income growth (Stock Titan).
Two pharma patient affordability program clients made up about 10% and 17% of accounts receivable as of June 30, 2025, leaving Paysign exposed to customer concentration risk (Stock Titan).
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2025.
Paysign Financial Performance
Revenues and expenses
Paysign Earnings Performance
Company profitability
Paysign News
AllArticlesVideos
Paysign to Host Third Quarter 2025 Earnings Call
Business Wire3 days ago
Paysign, Inc. Appoints Jose Garcia as Executive Vice President, Life Science Solutions
Business Wire4 weeks ago
Paysign, Inc. Announces Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Paysign stock?
Paysign (PAYS) has a market cap of $301M as of October 17, 2025.
What is the P/E ratio for Paysign stock?
The price to earnings (P/E) ratio for Paysign (PAYS) stock is 46.01 as of October 17, 2025.
Does Paysign stock pay dividends?
No, Paysign (PAYS) stock does not pay dividends to its shareholders as of October 17, 2025.
When is the next Paysign dividend payment date?
Paysign (PAYS) stock does not pay dividends to its shareholders.
What is the beta indicator for Paysign?
Paysign (PAYS) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.